Position in EOLS
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$123,532
+$49,573 QoQ
Shares Held
17,800
-1.1% QoQ
Ownership
0.027%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#86
of 158 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EOLS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Pure Financial Advisors, LLC holds $920,118 across 6 Drug Manufacturers - Specialty & Generic names. EOLS ranks #4 (13.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
1,662 | $280,113 | |
| 2 | TAK |
Takeda Pharmaceutical Co Ltd
|
16,991 | $272,365 | |
| 3 | HLN |
Haleon plc
|
14,133 | $131,860 | |
| 4 | EOLS |
Evolus, Inc.
This page
|
17,800 | $123,532 | |
| 5 | AQST |
Aquestive Therapeutics, Inc.
|
20,222 | $84,123 | |
| 6 | CRON |
Cronos Group Inc.
|
10,117 | $28,125 |
All Filings in EOLS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $123,532 | 17,800 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $73,959 | 17,995 | Shares | Sole | 2026-04-10 | |
| 2025-12-31 | $118,370 | 17,800 | Shares | Sole | 2026-02-04 | |
| 2025-09-30 | $109,500 | 17,834 | Shares | Sole | 2025-10-20 | |
| No filing history on record for this holder in this stock. | ||||||